1146629-77-7

Basic information

• Product Name: [4-(1H-Pyrazol-4-yl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl]methyl pivalate
• Synonyms: [4-(1H-Pyrazol-4-yl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl]methyl pivalate
• CAS NO: 1146629-77-7
• Molecular Formula: C₁₅H₁₇N₅O₂
• Molecular Weight: 299.32778
• EINECS: 1592732-453-0
• Mol File: 1146629-77-7.mol
• Article Data: 7

Chemical Properties

• Boiling Point: 536.7±50.0 °C(Predicted)
• Appearance: /
• Density: 1.33±0.1 g/cm3(Predicted)
• Storage Temp.: 2-8°C
• PKA: 10.76±0.50(Predicted)
• CAS DataBase Reference: [4-(1H-Pyrazol-4-yl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl]methyl pivalate(CAS DataBase Reference)
• NIST Chemistry Reference: [4-(1H-Pyrazol-4-yl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl]methyl pivalate(1146629-77-7)
• EPA Substance Registry System: [4-(1H-Pyrazol-4-yl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl]methyl pivalate(1146629-77-7)

Safety Data

• Hazardous Substances Data: 1146629-77-7(Hazardous Substances Data)

Usage

Chemical Properties

Type of white solid

Upstream product

• 1146629-76-6 [4-[1-(1-ethoxyethyl)-1H-pyrazol-4-yl]-7H-pyrrolo[2,3-d]pyrimidin-7-yl]methyl pivalate 
• 3680-69-1 4-chloro-1H-pyrrolo[2,3-d]pyrimidine 
• 1146629-75-5 (4-chloro-7H-pyrrolo[2,3-d]pyrimidin-7-yl)methyl 2,2-dimethylpropanoate 
• 18997-19-8 Chloromethyl pivalate 
• 55052-28-3 4-chloro-7-azaindole 
• 269410-08-4 pyrazole-4-boronic acid pinacol ester 

Downstream Products

• 1187595-90-9 (4-{1-[3-(cyanomethyl)-1-(ethylsulphonyl)azetidin-3-yl]-1H-pyrazol-4-yl}-7H-pyrrolo[2,3-d]pyrimidin-7-yl)methyl 2,2-dimethylpropanoate 
• 1187594-09-7 Baricitinib 

Relevant articles and documents

BARICITINIB INTERMEDIATE, METHOD FOR FORMING BARICITINIB INTERMEDIATE, AND METHOD FOR PREPARING BARICITINIB OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF

The present disclosure provides a Baricitinib intermediate, a method for preparing the Baricitinib intermediate, and a method for preparing Baricitinib or a pharmaceutically acceptable salt thereof using the Baricitinib intermediate. The method for preparing the Baricitinib intermediate involves the use of a divalent palladium catalyst or a nickel catalyst and provides the Baricitinib intermediate in high yield.

JAK KINASE INHIBITOR AND PREPARATION METHOD AND USE THEREOF

Provided in the present invention are a new type JAK kinase selective inhibitor and a preparation method and the use thereof. In particular, disclosed are a compound having the structure as shown in chemical formula (I) as a JAK kinase inhibitor or a stereoisomer or a tautomer thereof, or a pharmaceutically acceptable salt, a hydrate or a solvate thereof.

PROCESSES FOR PREPARING JAK INHIBITORS AND RELATED INTERMEDIATE COMPOUNDS

The present invention is related to processes for preparing chiral substituted pyrazolyl pyrrolo[2,3-d]pyrimidines of Formula III, and related synthetic intermediate compounds. The chiral substituted pyrazolyl pyrrolo[2,3-d]pyrimidines are useful as inhibitors of the Janus Kinase family of protein tyrosine kinases (JAKs) for treatment of inflammatory diseases, myeloproliferative disorders, and other diseases.